Perspectives in biology and medicine
Rizack MA.
PMID: 3452199
Perspect Biol Med. 1987;30(4):581-5. doi: 10.1353/pbm.1987.0029.
No abstract available.
Cite
Rizack MA. Evaluating and reevaluating drugs. Perspect Biol Med. 1987;30(4):581-5doi: 10.1353/pbm.1987.0029.
Rizack, M. A. (1987). Evaluating and reevaluating drugs. Perspectives in biology and medicine, 30(4), 581-5. https://doi.org/10.1353/pbm.1987.0029
Rizack, M A. "Evaluating and reevaluating drugs." Perspectives in biology and medicine vol. 30,4 (1987): 581-5. doi: https://doi.org/10.1353/pbm.1987.0029
Rizack MA. Evaluating and reevaluating drugs. Perspect Biol Med. 1987;30(4):581-5. doi: 10.1353/pbm.1987.0029. PMID: 3452199.
Copy
Download .nbib
The American journal of nursing
Meyer C.
PMID: 1536208
Am J Nurs. 1992 Mar;92(3):65-9. doi: 10.1097/00000446-199203000-00017.
No abstract available.
Cite
Meyer C. New drugs. The class of 1991, continued. Am J Nurs. 1992;92(3):65-9doi: 10.1097/00000446-199203000-00017.
Meyer, C. (1992). New drugs. The class of 1991, continued. The American journal of nursing, 92(3), 65-9. https://doi.org/10.1097/00000446-199203000-00017
Meyer, C. "New drugs. The class of 1991, continued." The American journal of nursing vol. 92,3 (1992): 65-9. doi: https://doi.org/10.1097/00000446-199203000-00017
Meyer C. New drugs. The class of 1991, continued. Am J Nurs. 1992 Mar;92(3):65-9. doi: 10.1097/00000446-199203000-00017. PMID: 1536208.
Copy
Download .nbib
Royal Society of Health journal
Turner P.
PMID: 1208775
R Soc Health J. 1975 Dec;95(6):302-3. doi: 10.1177/146642407509500614.
No abstract available.
Cite
Turner P. Advances in drugs--boon or curse? The balance sheet of modern drug therapy. R Soc Health J. 1975;95(6):302-3doi: 10.1177/146642407509500614.
Turner, P. (1975). Advances in drugs--boon or curse? The balance sheet of modern drug therapy. Royal Society of Health journal, 95(6), 302-3. https://doi.org/10.1177/146642407509500614
Turner, P. "Advances in drugs--boon or curse? The balance sheet of modern drug therapy." Royal Society of Health journal vol. 95,6 (1975): 302-3. doi: https://doi.org/10.1177/146642407509500614
Turner P. Advances in drugs--boon or curse? The balance sheet of modern drug therapy. R Soc Health J. 1975 Dec;95(6):302-3. doi: 10.1177/146642407509500614. PMID: 1208775.
Copy
Download .nbib
Nursing
Hussar DA.
PMID: 2027568
Nursing. 1991 May;21(5):41-5. doi: 10.1097/00152193-199105000-00016.
No abstract available.
Cite
Hussar DA. New drugs. Nursing. 1991;21(5):41-5doi: 10.1097/00152193-199105000-00016.
Hussar, D. A. (1991). New drugs. Nursing, 21(5), 41-5. https://doi.org/10.1097/00152193-199105000-00016
Hussar, D A. "New drugs." Nursing vol. 21,5 (1991): 41-5. doi: https://doi.org/10.1097/00152193-199105000-00016
Hussar DA. New drugs. Nursing. 1991 May;21(5):41-5. doi: 10.1097/00152193-199105000-00016. PMID: 2027568.
Copy
Download .nbib
BMJ (Clinical research ed.)
Tanne JH.
PMID: 18436943
BMJ. 2008 Apr 26;336(7650):913. doi: 10.1136/bmj.39559.404560.DB.
No abstract available.
Cite
Tanne JH. FDA works with US health insurers to identify drug problems. BMJ. 2008;336(7650):913doi: 10.1136/bmj.39559.404560.DB.
Tanne, J. H. (2008). FDA works with US health insurers to identify drug problems. BMJ (Clinical research ed.), 336(7650), 913. https://doi.org/10.1136/bmj.39559.404560.DB
Tanne, Janice Hopkins. "FDA works with US health insurers to identify drug problems." BMJ (Clinical research ed.) vol. 336,7650 (2008): 913. doi: https://doi.org/10.1136/bmj.39559.404560.DB
Tanne JH. FDA works with US health insurers to identify drug problems. BMJ. 2008 Apr 26;336(7650):913. doi: 10.1136/bmj.39559.404560.DB. PMID: 18436943; PMCID: PMC2335212.
Copy
Download .nbib
Nursing
Hussar DA.
PMID: 6899893
Nursing. 1980 May;10(5):24-32. doi: 10.1097/00152193-198005000-00006.
No abstract available.
Cite
Hussar DA. New drugs. Nursing. 1980;10(5):24-32doi: 10.1097/00152193-198005000-00006.
Hussar, D. A. (1980). New drugs. Nursing, 10(5), 24-32. https://doi.org/10.1097/00152193-198005000-00006
Hussar, D A. "New drugs." Nursing vol. 10,5 (1980): 24-32. doi: https://doi.org/10.1097/00152193-198005000-00006
Hussar DA. New drugs. Nursing. 1980 May;10(5):24-32. doi: 10.1097/00152193-198005000-00006. PMID: 6899893.
Copy
Download .nbib
Molecular diversity
Sharma R.
PMID: 32415493
Mol Divers. 2021 May;25(2):801-810. doi: 10.1007/s11030-020-10059-5. Epub 2020 May 15.
The utilization of approved medication is a requisite to combat certain diseases for health; however, the undesirable adverse effects (AEs) due to medication are generally unavoidable. Hypertension is one of such AEs resulting from approved medication in which blood...
Cite
Sharma R. Data science-driven analyses of drugs inducing hypertension as an adverse effect. Mol Divers. 2020;25(2):801-810doi: 10.1007/s11030-020-10059-5.
Sharma, R. (2021). Data science-driven analyses of drugs inducing hypertension as an adverse effect. Molecular diversity, 25(2), 801-810. https://doi.org/10.1007/s11030-020-10059-5
Sharma, Reetu. "Data science-driven analyses of drugs inducing hypertension as an adverse effect." Molecular diversity vol. 25,2 (2021): 801-810. doi: https://doi.org/10.1007/s11030-020-10059-5
Sharma R. Data science-driven analyses of drugs inducing hypertension as an adverse effect. Mol Divers. 2021 May;25(2):801-810. doi: 10.1007/s11030-020-10059-5. Epub 2020 May 15. PMID: 32415493.
Copy
Download .nbib
